Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
The company has launched the product, a generic version of Par Pharmaceuticals' Vasostrict, in the US market after getting approval from the US Food and Drug Administration (USFDA).
"We are pleased to provide this important authorised generic product to patients, especially in these difficult times of COVID-19," Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
According to IQVIA Health, Vasostrict brand had sales of around USD 878.5 million for the most recent twelve months ending December 2021.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
2 Indians Arrested With Drugs Worth $10 Million In US How El Chapo's Son Helped US Arrest Famous Narco Chief El Mayo Mexican Drug Lord 'El Mayo' And El Chapo's Son Arrested In US 150 mg Semen In Kolkata Doctor's Body, Suspect Gang-Rape: Parents To Court Tear Gas Fired After Kolkata Protest Against Doctor's Rape-Murder Turns Violent 2 French Rafale Jets Collide Mid-Air, Instructor, Pilot Missing Bangladeshi Students On Alert, To Remain On Streets To Resist Chaos India's 78th Independence Day: A Tribute By Google Doodle "Full Of Negativity...": PM Slams Opposition In Independence Day Speech Track Latest News Live on NDTV.com and get news updates from India and around the world.